Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Andrew S. Levey(Tufts Medical Center), Kerry Willis(National Kidney Foundation), Vlado Perkovic(The George Institute for Global Health), Hiddo J.L. Heerspink(University Medical Center Groningen), Morgan E. Grams(Johns Hopkins University), Dick de Zeeuw, Adeera Levin(Providence Health Care), Josef Coresh(New York University), Edward F. Vonesh(Northwestern University), Lesley A. Inker(Tufts University), Hocine Tighiouart(Tufts University), Luxia Zhang(Peking University), Kai‐Uwe Eckardt(Friedrich-Alexander-Universität Erlangen-Nürnberg), Yingying Sang(Johns Hopkins University), Shoshana H. Ballew(Johns Hopkins University), Tom Manley(National Kidney Foundation), Kunihiro Matsushita(Johns Hopkins University), Ron T. Gansevoort, Jian Ying(University of Utah), Tom Greene(University Medical Center Groningen)
Cited by 561
Related Papers
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11k
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k